Supplementary Appendix of

Accuracy and usability of saliva and nasal rapid antigen self-testing for detection of SARS-CoV-2 infection in the general population: a head-to-head comparison

Ewoud Schuit, Roderick P Venekamp, Irene K Veldhuijzen, Wouter van den Bijllaardt, Suzan D Pas, Joep J J M Stohr, Esther B Lodder, Marloes Hellwich, Richard Molenkamp, Zsofia Igloi, Constantijn Wijers, Irene H Vroom, Carla R S Nagel-Imming, Wanda G H Han, Jan AJW Kluytmans, Susan van den Hof, Janneke H H M van de Wijgert, Karel G M Moons

Table of contents

Supplementary material 1: short questionnaire after performing both self-tests at home	2
Supplementary material 2: short questionnaire provided 10 days after test site visit	5
Supplementary material 3: Specimen collection, SARS-CoV-2 diagnostic testing, and SARS-CoV-2 virus culture procedures	6
Table S1 2x2 tables for primary and secondary analyses of the molecular reference test – saliva Ag-RDT comparison	8
Table S2 2x2 tables for primary and secondary analyses of the molecular reference test – nasal Ag-RDT comparison	9
Table S3 Follow-up information of participants that were tested again within 10 days after the initial test.	10
Figure S1 Sensitivities with 95% confidence intervals of the antigen rapid test-molecular reference standard test comparisons at viral load cut-off for infectiousness	11
Figure S2 Distribution of viral loads in participants with a positive molecular reference test, stratified by symptomatology at time of sampling.	12

Supplementary material 1: short questionnaire after performing both self-tests at home (translated from Dutch)

- 1. What was the result of the saliva self-test?
 - Negative
 - Positive
 - I don't know: could not perform the test
 - I don't know: could not read the test result
 - Other,
- 2. What was the result of the nasal self-test?
 - Negative
 - ____ Positive
 - I don't know: could not perform the test
 - I don't know: could not read the test result
 - Other,
- 3. What is the reason for testing?
 - Multiple answers possible
 - I have (had) Covid-19 like symptoms
 - I am a close contact of a SARS-CoV-2 infected person
 - Date of last contact: ____ ___ (day month)
 - I was notified because of:
 - The infected person is a household member \Box yes / \Box no
 - Received notification by CoronaMelder app (English: Corona notification app) \square yes / \square no
 - Received notification by public health service (by phone or letter) \Box yes / \Box no
 - Received notification by SARS-CoV-2 infected person □ yes / □ no
 - Other,
 - GP recommended a SARS-CoV-2 test
 - Travelled to a high-pandemic country
 - I performed a self-test and tested positive
 - What was the date of the positive self-test: ____ ___ (day month)
 - ☐ None of the above, but......
- 4. Did you receive a Covid-19 vaccination?
 - No No
 - Yes
 - If yes, which vaccine did you receive? Pfizer Moderna AstraZeneca Janssen Unknown
 - How many vaccinations did you receive? One Two
 What was the date of the last vaccination? (day month year)
- Did you have had a positive SARS-CoV-2 test previously? If yes, how long ago?
 No
 - - If yes, how long ago? $\square < 2$ months \square 2-6 months \square 6-12 months $\square > 12$ months
- At this moment, do you have any COVID-19 like symptoms?
 □ No GO TO QUESTION 9
 □ Yes
- 7. What COVID-19 like symptoms do you currently have? *Multiple answers possible*
 - Common cold
 - Shortness of breath
 - Fever
 - Coughing
 - Loss of taste or smell
 - Muscle ache
 - I have other symptoms:

What was the moment you first experienced these symptoms? 8.

Today
Yesterday
Two days ago
Three or more days ago

- 9. What is your highest level of education?
 - Primary

 - Secondary
 College / University, Bachelor's Degree
 College / University, Master's Degree
- 10. The saliva self-test instruction indicates you cannot eat, drink, smoke, brush your teeth or chew gum 30 minutes prior to the test, did you follow this instruction?

	 Yes No If no, I Multiple answer Ate 	rs possib	le					
	☐ drank ☐ ☐ chewed gum				brushe	ed	my	smoked teeth
11.	On a scale from 1 (w	ery easy) to 5 (ve	ery hard),	how diff	icult was	s it to perform the saliva self-test?	
	Very easy	1	2	3	4	5	very hard	
12.	On a scale from 1 (w	ery easy) to 5 (ve	ery hard),	how diff	icult was	s it to read the result off the saliva s	elf-test?
	Very easy	1	2	3	4	5	very hard	
13.	On a scale from 1 (w	ery easy) to 5 (ve	ery hard),	how diff	icult was	s it to perform the nasal self-test?	
	Very easy	1	2	3	4	5	very hard	
14.	On a scale from 1 (v	ery easy) to 5 (ve	ery hard),	how diff	icult was	s it to read the result off the nasal se	elf-test?
	Very easy	1	2	3	4	5	very hard	
15.	Do you agree with the	he follow	ving state	ements?				
	The instruction for u Agree	use of the In doub		elf-test w Disagre				
	I am confident I pert Agree	formed th In doub		self-test Disagre	•			
	I would use this sali Agree	va self-te <i>In doub</i>		ne if I con Disagre				

- 16. Do you prefer the saliva or nasal self-test?

 - No
 Yes, I prefer the saliva self-test
 Yes, I prefer the nasal self-test

 - If yes, why?

17. Do you have suggestions for improvement of the instruction for use of the saliva self-test or other suggestions?

.....

Supplementary material 2: short questionnaire provided 10 days after test site visit (translated from Dutch)

- 1. Did you develop any Covid-19 like symptoms since your last corona test 10 days ago (see next question for list of possible symptoms)?
 - □ No □ Yes
- 2. What COVID-19 like symptoms do you currently have?
 - Multiple answers possible
 Common cold
 Shortness of breath
 Fever
 Coughing
 - Loss of taste or smell
 - Muscle ache
 - I have other symptoms:
- 3. What was the moment you first experienced these symptoms?
 - 🗌 Today
 - Yesterday
 - Two days ago
 - Three or more days ago
- 4. Did you perform a corona test or was a corona test performed in the last 10 days since your corona test at the test site and the two self-tests performed for this study?
 - No THIS CONCLUDES THIS QUESTIONNAIRE
 - Yes
 - If yes, what type of test was performed?
 - Test at a public health service test site

PCR	
(Rapid) a	intigen test
🗌 I don't ki	now
Test at a commen	rcial test site
D PCR	
(Rapid) a	intigen test
I don't ki	now
Self-test that I bo	ought myself
Other,	

5. What is the reason for testing?

Multiple answers possible

- I have (had) Covid-19 like symptoms
- I am a close contact of a SARS-CoV-2 infected person
- Date of last contact: _____ ____ (day month)
- I was notified because of:
- The infected person is a household member \Box yes / \Box no
- Received notification by CoronaMelder app (English: Corona notification app) \Box yes / \Box no
- Received notification by public health service (by phone or letter) \Box yes / \Box no
- Received notification by SARS-CoV-2 infected person \Box yes / \Box no
- Other,
- GP recommended a SARS-CoV-2 test
- Travelled to a high-pandemic country
- I performed a self-test and tested positive
- What was the date of the positive self-test: ____ ___ (day month)
- None of the above, but.....
- 6. What was the result of the corona test?
 - Positive (SARS-CoV-2 infection present)
 - □ Negative
 - No test result (test failed)

Supplementary material 3: Specimen collection, SARS-CoV-2 diagnostic testing, and SARS-CoV-2 virus culture procedures

Specimen collection and SARS-CoV-2 diagnostic testing procedures

West Brabant region, Microvida laboratories at Bravis hospital in Roosendaal; samples from Roosendaal

One superficial combined oropharyngeal and nasal swab (about 2.5 cm deep from the edge of the nostril) was taken per person at the Public Health Service test sites at the test sites in Roosendaal, placed in universal transport media (HiViralTM) with MagnaPure LC lysis- and binding buffer (Roche Diagnostics, The Netherlands), and transported to the Microvida laboratory in Roosendaal. RT-PCR was used as the reference standard test. RT-PCR was performed using the cobas SARS-CoV-2 test on the cobas 8800 platform (Roche Diagnostics International, Rotkreuz, Switzerland). Cycle threshold (Ct) values for the SARS-CoV-2 E-gene were converted to viral load (genome copies/ml) using an in-house established standard curve. The assay was used in accordance with the manufacturer's instructions; amplification curves and Ct values were interpreted using the manufacturer's interpretation algorithms, which complied with the European in-vitro diagnostic devices directive.

Central- and Northeast Brabant region, Microvida laboratories at Elisabeth Twee Steden Ziekenhuis (ETZ) in Tilburg; samples from Tilburg

One deep combined oropharyngeal-nasopharyngeal swab (>5 cm deep from the edge of the nostril) was taken per person at the Public Health Service test site in Tilburg, placed in 1x Tris-EDTA buffer (Sigma-Aldrich), and transported to the Microvida laboratory in Tilburg. One of two molecular tests were used as the reference test: the SARS-CoV-2 assay on the Alinity M molecular platform (Abbott) according to manufacturer's instructions, or an in-house RT-PCR as previously described using automated DNA extraction on a Qiagen Symphony with subsequent RT-PCR on a Qiagen Rotor-Gene platform.¹ RT-PCR positive samples were further analyzed on a cobas 8800 platform (in the Microvida laboratory in Roosendaal) to obtain Ct values for viral load calculation. Samples were stored at -80°C within 24 hours and thawed once for the cobas 8800 analysis.² In case of discrepant results (Alinity/in-house positive, cobas 8800 negative), a Ct value of 40 was assigned for subsequent analysis.

Rotterdam city region, Erasmus Medical Center Viroscience laboratory: samples from south of Rotterdam (Zuidland)

One deep combined OP-N swab (>5 cm deep from the edge of the nostril) swab was taken per person at the Public Health service test site in the Rotterdam-Rijnmond region (Zuidland), placed directly in universal transport media (HiViralTM), and transported to the Erasmus MC Viroscience diagnostic laboratory. RT-PCR was used as the reference standard test. RT-PCR testing was performed in virus transport medium using the cobas SARS-CoV-2 test on the cobas 6800 platform. The assay was used in accordance with the manufacturer's instructions; amplification curves and cycle threshold values were interpreted using the manufacturer's interpretation algorithms, which complied with the European in-vitro diagnostic devices directive.

Viral load calculation

We used a viral load cut-off as a proxy of infectiousness of $\geq 5.2 \log 10$ SARS-CoV-2 E-gene copies/mL, which was the viral load cut-off above which 95% of people with a positive molecular test had a positive virus culture in a recent previous study by our group.¹ For that study, the Erasmus MC Viroscience laboratory created a standard curve by testing dilutions of a specific quantified E-gene transcript (primary standard) available from the European Virus Archive (EVAg⁴) with the RT-PCR described by Corman et al.³ The relation between Ct value and number of E-gene copies/ml was determined by linear regression analysis. Based on this calibration curve a secondary standard derived from cell-cultured virus was prepared and quantified. Serial dilutions of this secondary standard were tested by RT-PCR to prepare a secondary standard curve by linear regression.

In that previous study, we determined whether the cobas PCR platform at the Microvida laboratory provided comparable data to the cobas PCR platform at the Erasmus Medical Center Viroscience laboratory by having both laboratories test the same SARS-CoV-2 viral load panel obtained from the National Public Health Institute (RIVM). The Ct values generated in the two laboratories corresponded well. Therefore, we concluded that the same formula to convert Ct values into viral loads (copies/ml) could be used for the West-Brabant and Rotterdam laboratories This formula was $62.5 * e^{\frac{43.1-Ct}{1.607}}$. The Microvida laboratory used different medium/reagent volumes per swab depending on the location. For each, a factor *X* was calculated based on the swab volume, dilution, and total sample volume, to allow alignment across samples with respect to the viral load in the Rotterdam standard. For example, if the sample volume is equal (3 ml in Tilburg compared to 3 ml in Rotterdam), but the dilution factor is higher, e.g., by the addition of lysis buffer (3 in Tilburg compared to 2 in Rotterdam), the effective viral sample would be lower than in the Rotterdam standard, thereby underestimating the actual viral load when using the above formula. To account for this, a factor *X* < 1 was used, here 6/9. If dilution was lower, a factor *X* > 1 was used. The conversion formula used therefore was $62.5 * e^{\frac{43.1-Ct}{1.607}} / X$.

Self-tests

Saliva Ag-RDT

The saliva Ag-RDT used in this study was the COVID-19 Antigen Rapid Test (Oral Fluid) for Self-testing by Hangzhou AllTest Biotech Co., Ltd., a CE-marked Ag-RDT. According to the instructions for use, participants had to cough deeply 3 to 5 times after which saliva could be spit in the test tube. After addition of buffer fluid, and squeezing the test tube 10-15 times, two droplets of the solvent could be added to the testing cassette. After 15 minutes, but no later than 20 minutes, the participant could read the test result visually from the testing cassette.

Nasal Ag-RDT

The nasal Ag-RDT used in this study was the SD Biosensor SARS-CoV-2 Rapid Antigen Self-Test Nasal, distributed by Roche Diagnostics, a CE-marked Ag-RDT. According to the instructions for use, a sample should be taken by placing a nasal swab 2 cm deep in the nose and twisting it 4 times for 15 seconds, once in each nostril. Afterwards the nose swab had to be placed in a test tube that was filled by buffer fluid and twisted 10 times during which the test tube had to be squeezed lightly. While squeezing the tube, the swab could be removed from the tube, while leaving all the test fluid in the tube. Then, 4 droplets of the solvent had to be added to the testing cassette. After 15 minutes, but no later than 30 minutes, the participant had to read the test result visually from the testing cassette.

Analytical performance

The analytical performances of the Hangzhou AllTest Biotech and the SD Biosensor lateral flow test devices were assessed using a national External Validation Quality Assessment panel (LEQA) for SARS-CoV-2 Ag-RDTs. The LEQA Ag panel contained four different SARS-CoV-2 strains, including:

hCoV-19/Netherlands/NoordBrabant_10003/2020 (B.11, 19A);

hCoV-19/Netherlands/GE-RIVM-20300/2020 (B.1.177, 20AEU1);

hCoV-19/Netherlands/NH-RIVM-20432/2020 (B.1.1.7, 20B/501Y.V1); and

hCoV-19/Netherlands/NB-RIVM-20274/2020 (B.1.5, 20A).

These strains had been deactivated by 2-hour incubation with Triton X-100 at room temperature.

The results of the panel assessment are presented in the Table below and show that both devices had good analytical performance. Furthermore, the analytical performance of the two devices were very similar.

LEQA Ag panel	SARS-CoV-2 strain	Concentration	Hangzhou AllTest	SD Biosensor
		TCID50/ml	Biotech	
LEQAA1_Ag21-01	B.1.177 20A.EU1	1334	++	++
LEQAA1_Ag21-02	B.11; 19A; wildtype	7499	++	++
LEQAA1_Ag21-03	B.1.1.7 20B/501Y.V1	23714	++	++
LEQAA1_Ag21-04	B.11; 19A; wildtype	75	+	(+)
LEQAA1_Ag21-05	B.1.1.7 20B/501Y.V1	237	+	+
LEQAA1_Ag21-06	B.1.177 20A.EU1	13335	++	++
LEQAA1_Ag21-07	B.1.5 20A	2371	++	++
LEQAA1_Ag21-08	B.1.177 20A.EU1	133	++	+
LEQAA1_Ag21-09	Negative		-	-
LEQAA1_Ag21-10	B.1.1.7 20B/501Y.V1	2371	++	++
LEQAA1_Ag21-11	B.11; 19A; wildtype	7	(+)	-
LEQAA1_Ag21-12	B.1.5 20A	23714	++	++
LEQAA1_Ag21-13	B.11; 19A; wildtype	750	++	+
LEQAA1_Ag21-14	B.1.5 20A	237	++	+
LEQAA1_Ag21-15	B.11; 19A; wildtype	74989	++	++

TCID50 = Median Tissue Culture Infectious Dose

- = negative; (+) = faint positive; + = positive; ++ = strong positive

References

1. Kluytmans-van den Bergh MFQ, Buiting AGM, Pas SD, et al. Prevalence and Clinical Presentation of Health Care Workers With Symptoms of Coronavirus Disease 2019 in 2 Dutch Hospitals During an Early Phase of the Pandemic. *JAMA Netw Open* 2020; **3**(5): e209673.

2. Stohr J, Wennekes M, van der Ent M, et al. Clinical performance and sample freeze-thaw stability of the cobas(R)6800 SARS-CoV-2 assay for the detection of SARS-CoV-2 in oro-/nasopharyngeal swabs and lower respiratory specimens. *J Clin Virol* 2020; **133**: 104686.

Table S1 2x2 tables for primary and secondary analyses of the molecular reference test – saliva Ag-RDT
comparison

Analysis	Subgroup				
Primary	8		Ref+	Ref-	Total
·		Test+	85	26	111
		Test-	97	2595	2692
		Total	182	2621	2803
Secondary (stratified):					
Infectiousness viral load cut-off¶		_	Ref+	Ref-	Total
		Test+	78	32	110
		Test-	64	2614	2678
		Total	142	2646	2788
Symptoms present at sampling:	Yes		Ref+	Ref-	Total
Symptoms present at sampning ₊ .	103	Test+	77	25	102
		Test-	74	2130	2204
		Total	151	2155	2306
	No		Ref+	Ref-	Total
		Test+	8	1	9
		Test-	23	452	475
		Total	31	453	484
Vaccinated (at least 1 one)@:	Yes		Ref+	Ref-	Total
. accinated (at reast 1 one) .	105	Test+	54	22	76
		Test-	61	2253	2314
		Total	115	2275	2390
	No		Ref+	Ref-	Total
		Test+	31	4	35
		Test-	36	333	369
		Total	67	337	404
Providuo SADS CoV 2 infections	Vac		Daf	Daf	Total
Previous SARS-CoV-2 infection [§] :	Yes	Test+	Ref+ 4	Ref- 3	Total 7
		Test-	4 16	3 343	359
		Total	20	346	366
		Total	20	540	500
	No		Ref+	Ref-	Total
		Test+	81	23	104
		Test-	81	2242	2323
		Total	162	2265	2427
с. †	F 1		D C	ъć	
Sex [†] :	Female	T	Ref+	Ref-	Total
		Test+	41	13	54
		Test-	67 108	1590	1657
		Total	108	1603	1711
	Male		Ref+	Ref-	Total
		Test+	44	13	57
		Test-	29	995	1024
		Total	73	1008	1081
A F 1#			ъć	ъć	m · •
Age [years] [#] :	≥ 16 to ≤ 40	T - • •	Ref+	Ref-	Total
		Test+	38	15	53
		Test-	54 92	1343	1397
		Total	92	1358	1450
	>40 to ≤65		Ref+	Ref-	Total
		Test+	36	9	45
		Test-	36	1054	1090
		Total	72	1063	1135
	~ -		Р ć	Б ć	
	>65	Tatt	Ref+	Ref-	Total
		Test+ Test-	11 6	2 189	13 195
			6 17	189	195 208
Viral load cut-off for infectiousness, d		Total			

Total
 17
 191
 208

 ¶Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture⁶, was 5.2 log10 SARS-CoV-2 E-gene copies/mL. Viral load unavailable for 19 individuals.

 \$Symptoms not available for 13 participants.
 (a) COVID-19 vaccination status not available for 9 participants.

 \$Previous SARS-CoV-2 infection information not available for 10 participants.
 *

 * Sex not available for 11 participants.
 *

 * Age not available for 10 participants.
 *

rimary	P	Test+ Test- Total	Ref+ 124 56 180	Ref- 12 2627 2639	Total 136 2683 2819
Secondary (stratified):		10141	100	2039	2017
Infectiousness viral load cut-off			Ref+	Ref-	Total
"		Test+	120	13	133
		Test-	23	2648	2671
		Total	143	2661	2804
Symptoms present at sampling:	Yes		Ref+	Ref-	Total
		Test+	117	10	127
		Test-	32	2160	2192
		Total	149	2170	2319
	No		Ref+	Ref-	Total
		Test+	7	2	9
		Test-	24	454	478
		Total	31	456	487
Vaccinated (at least 1 one) [@] :	Yes		Ref+	Ref-	Total
		Test+	75	10	85
		Test-	32	2272	2304
		Total	107	2282	2389
	No		Ref+	Ref-	Total
		Test+	49	2	51
		Test-	24	346	370
		Total	73	348	421
revious SARS-CoV-2 infection [§] :	Yes		Ref+	Ref-	Total
		Test+	7	3	10
		Test-	12	350	362
		Total	19	353	372
	No	-	Ref+	Ref-	Total
		Test+	117	9	126
		Test-	44	2267	2311
		Total	161	2276	2437
ex [†] :	Female	T	Ref+	Ref-	Total
		Test+	73	7	80
		Test-	33	1604	1637
		Total	106	1611	1717
	Male	Tatt	Ref+	Ref-	Total
		Test+	51 22	5 1012	56 1034
		Test-	22 73	1012	1034
		Total	73	1017	1090
ge [years] [#] :	≥ 16 to ≤ 40	Test	Ref+	Ref-	Total
		Test+	62 21	7	69 1204
		Test-	31	1363	1394
		Total	93	1370	1463
	>40 to ≤ 65	Tatt	Ref+	Ref-	Total
		Test+	51	4	55 1084
		Test- Total	19 70	1065 1069	1084 1139
		Total			
	<u>\65</u>	Total	Ref	Ref	Total
	>65		Ref+	Ref-	Total
	>65	Test+ Test-	Ref+ 11 5	Ref- 1 189	Total 12 194

Subgroup

Table S2 2x2 tables for primary and secondary analyses of the molecular reference test - nasal Ag-RDT comparison

 Iotal
 16
 190
 206

 ¶Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture⁶, was 5.2 log10 SARS-CoV-2 E-gene copies/mL. Viral load unavailable for 19 individuals.

 \$Symptoms not available for 13 participants.

 @ COVID-19 vaccination status not available for 9 participants.

 \$Previous SARS-CoV-2 infection information not available for 10 participants.

 * Sex not available for 12 participants.


Analysis

[#]Age not available for 11 participants.

Table S3 Follow-up information of participants that were tested again within 10 days after the initial test. Information was not available for 794 (28.3%) and 796 (28.2%) of participants with saliva and nasal Ag-RDT result available, respectively. Of the remaining participants 1758 (87.5%) and 1772 (87.6%) were not tested within 10 days after the initial test.

Test result available from the reference test and	Saliva Ag-RDT	Nasal Ag-RDT
Sample size (Test during 10-day follow-up)	N = 251/2009 (12.5%)	N = 251/2029 (12.4%)
Testing information, n (%) ¹		
Symptomatic	74 (29.5)	74 (29.5)
Asymptomatic - close contact of confirmed SARS-CoV-2 infected household member	0 (0.0)	0 (0.0)
Asymptomatic - close contact of other confirmed SARS-CoV-2 infected individual	40 (15.9)	41 (16.3)
Asymptomatic – other	137 (54.6)	136 (54.2)
Type of test, n (%)		
public health service COVID-19 test sites	71 (28.3)	70 (27.9)
RT-PCR test	44 (62.0)	44 (62.9)
Ag-RDT	2 (2.8)	2 (2.9)
Unknown	25 (35.2)	24 (34.2)
Commercial test site	24 (9.6)	24 (9.6)
RT-PCR test	5 (20.8)	5 (20.8)
Ag-RDT	16 (66.7)	16 (66.7)
Unknown	3 (12.5)	3 (12.5)
Self-test	126 (50.2)	127 (50.6)
Other (e.g., via work, school)	30 (12.0)	30 (12.0)
Test result		
Positive	8 (3.2)	8 (3.2)
Negative	240 (95.6)	240 (95.6)
Unknown	3 (1.2)	3 (1.2)

Figure S1 Sensitivities with 95% confidence intervals of the antigen rapid test-molecular reference standard test comparisons at viral load cut-off for infectiousness (i.e., viral load <5.2 log10 SARS-CoV-2 E-gene copies/mL is considered as a negative reference test result), stratified according to symptomatology, COVID-19 vaccination status, previous infection status, sex, and age. The vertical line indicates the sensitivity of the Ag-RDT in the overall study population before application of a viral load cut-off (see Figure 2), and the number of positive molecular tests out of the total or subgroup between parentheses.



saliva self-test at infectiousness cut-off




Figure S2 Distribution of viral loads in participants with a positive molecular reference test, stratified by symptomatology at time of sampling.